HOME Top Market Reports Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

By: marketsandmarkets.com
Publishing Date: August 2015
Report Code: BT 3693

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global cancer biomarkers market has experienced substantial growth over the last couple of years. This market is expected to grow at a CAGR of 11.6% from 2015 to 2020. Factors such as rising incidence of cancer; technological advancements in omics technologies; favorable government funding for cancer research; increased demand for personalized medicines in cancer therapies; and increased use of biomarkers in drug discovery development and clinical trials are expected to fuel the growth of the cancer biomarkers market during the forecast period. However, poorly suited regulatory and reimbursement systems of biomarker tests, high capital investments for biomarker discovery and development, and sample collection and storage difficulties are restraining the growth of this market.

The global cancer biomarkers market is segmented on the basis of type of biomarkers, tumor type, profiling technologies, applications, and geography. Based on type, the market is segmented into protein biomarkers, genetic biomarkers, and others which include viral, cell, and carbohydrate biomarkers. Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other type of cancers such as Gastrointestinal Stromal Tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia. Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America and Middle East and Africa).

The Asia-Pacific market is poised to register the highest growth rate in the forecast period owing to the favorable government funding for cancer biomarker research, rising prevalence of cancer, increasing demand for advanced healthcare facilities in developing economies such as India and China, increasing number of clinical trials, and increasing focus of international players in emerging markets. The global cancer biomarkers market is consolidated in nature at the top. In order to maintain their market shares, leading players are continuously focusing on new product developments and upgrading their existing products to enhance their product portfolios. Increasing competition among major players is expected to drive innovation in the market, thereby helping the industry to overcome existing challenges in various applications such as diagnostics, drug discovery and development, personalized medicine, among others.

Major players in this market are Abbott Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd. (Switzerland), Illumina, Inc. (U.S.), Qiagen NV (Netherlands), Agilent Technologies (U.S.),  Thermo Fisher Scientific Inc. (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.).

Scope of the Report

Cancer biomarkers are molecules secreted by a tumor or a specific response of the body to the presence of cancer. These are substances or processes that are indicative of the presence of cancers in the human body, and enhance the cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics tools. The identification of cancer biomarkers is important to detect the tumors in the body.  These are used for diagnostics, drug discovery and development, prognostics, personalized medicine, and surrogate endpoints and are becoming an integral part of various industries such as pharmaceutical and clinical trial companies, due to their ability to reduce the time and cost of the drug discovery and development process and clinical trials.

Global Cancer Biomarkers Market

This research report categorizes the cancer biomarkers market into the following segments:

Global Cancer Biomarkers Market, by Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Others (Cell, Viral, and Carbohydrate Biomarkers)

Global Cancer Biomarkers Market, by Tumor Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others (Gastrointestinal stromal tumors (GIST), Lung, Ovarian, bladder, Pancreatic, Kidney, Melanoma, and Leukemia)

Global Cancer Biomarkers Market, by Profiling Technologies

  • Omics Technologies
    • Proteomics
      • Mass Spectrometry
      • 2D Gel Electrophoresis
      • Protein Microarray Technology
      • Antibody Array Technology
      • Peptide Array Technology
    • Genomics
      • Next Generation Sequencing (NGS)
      • Microarray
      • Polymerase Chain Reaction (PCR)
    • Other Omics Technologies (Metabolomics and Glycomics)
  • Imaging Technologies
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)
    • Computed Tomography
    • Mammography
    • Ultrasound
  • Immunoassays
    • Immunohistochemistry(IHC) Tests
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Flow Cytometry
  • Cytogenetics based tests
    • In situ Hybridization
    • Others (Karyotyping, AmpliChip and In Vitro Diagnostic Multivariate Index Assays (IVDMIA))
  • Bioinformatics

Global Cancer Biomarkers Market, by Applications

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others (Personalized Medicine, Surrogate endpoints, Recurrence, and Therapeutics)

Global Cancer Biomarkers Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Rest of the World (RoW)
    • Latin America
    • Middle East and Africa

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Stakeholders
    1.3 Market Scope
    1.4 Cancer Biomarkersmarkets Covered

2 Research Methodology (Page No. - 19)
    2.1 Research Approach
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Market Share Estimation
           2.4.1 Key Data From Secondary Sources
           2.4.2 Key Data From Primary Sources
           2.4.3 Key Industry Insights
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 32)

5 Market Overview (Page No. - 33)
    5.1 Introduction
    5.2 Market Segmentation
           5.2.1 Cancer Biomarkers Market, By Type
           5.2.2 Cancer Biomarkers Market, By Tumor Type
           5.2.3 Cancer Biomarkers Market, By Profiling Technologies
           5.2.4 Cancer Biomarkers Market, By Application
    5.3 Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Technological Advancements
                    5.3.1.2 Increasing Prevalence of Cancer
                    5.3.1.3 Enhanced Accuracy and Speed of Diagnosis
                    5.3.1.4 Increasing Use of Cancer Biomarkers in Drug Discovery and Development
                    5.3.1.5 Increasing Research on Cancer Biomarkers
                    5.3.1.6 Fda Support for Biomarker Development
           5.3.2 Restraints
                    5.3.2.1 Poorly Suited Regulatory and Reimbursement Systems
                    5.3.2.2 High Capital Investment and Low Benefit-Cost Ratio
                    5.3.2.3 Technical Issues Related to Sample Collection and Storage
           5.3.3 Opportunitites
                    5.3.3.1 Personalized Medicine
                    5.3.3.2 Companion Diagnostics
                    5.3.3.3 Emerging Economies
           5.3.4 Challenges
                    5.3.4.1 Proving Clinical Validity and Utility of Biomarker-Based Tests Leading to Their Insufficient Acceptance

6 Industry Trends (Page No. - 49)
    6.1 Introduction
    6.2 Industry Trends
           6.2.1 Increasing Use of Bimarkers for Developing Personalized Medicine
           6.2.2 Advancements in Omics Technologies
    6.3 Porter’s Five Forces Analysis
           6.3.1 Threat From New Entrants
           6.3.2 Threat From Substitutes
           6.3.3 Bargaining Power of Suppliers
           6.3.4 Bargaining Power of Buyers
           6.3.5 Intensity of Competitive Rivalry
    6.4 Strategic Benchmarking
           6.4.1 New Product Launches and Product Enhancements

7 By Tumor Type (Page No. - 55)
    7.1 Introduction
    7.2 Breast Cancer
    7.3 Lung Cancer
    7.4 Colorectal Cancer
    7.5 Prostate Cancer
    7.6 Cervical Cancer
    7.7 Other Cancers

8 Cancer Biomarkers Market, By Type (Page No. - 61)
    8.1 Introduction
    8.2 Protein Biomarkers
    8.3 Genetic Biomarkers
    8.4 Other Cancer Biomarkers

9 By Profiling Technologies (Page No. - 64)
    9.1 Introduction
    9.2 Immunoassays
           9.2.1 Elisa
           9.2.2 Immunohistochemistry (IHC)
           9.2.3 Flow Cytometry
    9.3 Omics Technologies
           9.3.1 Genomics
                    9.3.1.1 Next Generation Sequencing (NGS)
                    9.3.1.2 Microarrays
                    9.3.1.3 PCR (Polymer Chain Reaction)
           9.3.2 Proteomics
                    9.3.2.1 Mass Spectrometry
                               9.3.2.1.1 Maldi Mass Spectrometry
                               9.3.2.1.2 Imaging Mass Spectrometry
                    9.3.2.2 2-D Gel Electrophoresis
                    9.3.2.3 Protein Microarray Technology
                    9.3.2.4 Antibody Array Technology
                    9.3.2.5 Peptide Array Technology
           9.3.3 Other Omics Technologies
    9.4 Cytogenetics
           9.4.1 Ish (In Situ Hybridization)
           9.4.2 Others
    9.5 Imaging Technologies
           9.5.1 Magnetic Resonance Imaging (MRI)
           9.5.2 Positron Emission Tomography (PET)
           9.5.3 Mammography
           9.5.4 Computed Tomography (CT)
           9.5.5 Ultrasound
    9.6 Bioinformatics

10 By Application (Page No. - 88)
     10.1 Introduction
     10.2 Diagnostics
     10.3 Drug Discovery and Development
     10.4 Prognostics
     10.5 Risk Assessment
     10.6 Others

11 By Geographic Analysis (Page No. - 93)
     11.1 Introduction
     11.2 North America
             11.2.1 U.S.
             11.2.2 Canada
     11.3 Europe
             11.3.1 Germany
             11.3.2 U.K.
             11.3.3 France
             11.3.4 Italy
             11.3.5 Spain
             11.3.6 Rest of Europe (RoE)
     11.4 Asia-Pacific
             11.4.1 Japan
             11.4.2 China
             11.4.3 India
             11.4.4 Rest of Asia-Pacific (RoAPAC)
     11.5 Rest of the World (RoW)
             11.5.1 Latin America
             11.5.2 Middle East and Africa

12 Competitive Landscape (Page No. - 130)
     12.1 Overview
     12.2 Market Share Analysis, Global Cancer Biomarkers Market
     12.3 Competitive Situation and Trends
             12.3.1 New Product Launches
             12.3.2 Expansions
             12.3.3 Agreements, Partnerships, Collaborations, & Joint Ventures
             12.3.4 Mergers & Acquisitions

13 Company Profiles (Page No. - 140)
     13.1 Introduction
     13.2 Abbott Laboratories
             13.2.1 Business Overview
             13.2.2 Products Offered
             13.2.3 MnM View
             13.2.4 Recent Developments
     13.3 Affymetrix, Inc.
             13.3.1 Business Overview
             13.3.2 Products Offered
             13.3.3 MnM View
             13.3.4 Recent Developments
     13.4 Illumina, Inc.
             13.4.1 Business Overview
             13.4.2 Products Offered
             13.4.3 MnM View
             13.4.4 Recent Developments
     13.5 Qiagen N.V.
             13.5.1 Business Overview
             13.5.2 Qiagen N.V.: Company Snapshot
             13.5.3 Products Offered
             13.5.4 MnM View
             13.5.5 Recent Developments
     13.6 Roche Diagnostics Ltd.
             13.6.1 Business Overview
             13.6.2 Products Offered
             13.6.3 MnM View
             13.6.4 Recent Developments
     13.7 Agilent Technologies, Inc.
             13.7.1 Business Overview
             13.7.2 Products Offered
             13.7.3 MnM View
             13.7.4 Recent Developments
     13.8 Quest Diagnostics Inc.
             13.8.1 Business Overview
             13.8.2 Quest Diagnostics: Company Snapshot
             13.8.3 Products Offered
             13.8.4 Recent Developments
     13.9 Merck & Co. Inc.
             13.9.1 Business Overview
             13.9.2 Products Offered
             13.9.3 Recent Developments
     13.10 Hologic, Inc.
             13.10.1 Business Overview
             13.10.2 Products Offered
             13.10.3 Recent Developments
     13.11 Becton, Dickinson and Company
             13.11.1 Business Overview
             13.11.2 Product Portfolio
             13.11.3 Developmets

14 Appendix (Page No. - 167)
     14.1 Insights of Industry Experts
     14.2 Discussion Guide
     14.3 Available Customizations
     14.4 Related Reports
     14.5 Introducing RT: Real-Time Market Intelligence


List of Tables (191 Tables)

Table 1 Technological Advancments and Increasing Prevalence of Cancer to Fuel the Growth of Cancer Biomarkers Market
Table 2 Poorly Suited Regulatory and Reimbursement Systems are Hindering the Growth of Cancer Biomarkers Market
Table 3 Personalized Medicine and Emerging Markets Present an Array of Opportunitites for the Growth of Cancer Biomarkers Market
Table 4 Insufficient Acceptance, Proving Clinical Validity and Utility of Biomarker-Based Tests are A Major Challenge in the Cancer Biomarkers Market
Table 5 Global Cancer Biomarkers Market Size, By Tumor Type, 2013–2020 (USD Million)
Table 6 Global Breast Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 7 Global Lung Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 8 Global Colorectal Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 9 Global Prostate Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 10 Global Cervical Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 11 Global Cancer Biomarkers Market for Other Cancers, By Country/Region, 2013-2020 (USD Million)
Table 12 Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 13 Protein Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 14 Genetic Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 15 Other Cancer Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 16 Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 17 Global Immunoassay Market Size, By Type, 2013-2020 (USD Million)
Table 18 Global Immunoassays Market Size, By Country/Region, 2013-2020 (USD Million)
Table 19 Global Elisa Market Size, By Country/Region, 2013-2020 (USD Million)
Table 20 Global IHC Market Size, By Country/Region, 2013-2020 (USD Million)
Table 21 Global Flow Cytometry Market, By Country/Region, 2013-2020 (USD Million)
Table 22 Global Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 23 Global Omics Technologies Market Size, By Country, 2013-2020 (USD Million)
Table 24 Global Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 25 Global Genomics Technologies Market Size, By Country/Region (USD Million)
Table 26 Global NGS Market Size, By Country/Region, 2013-2020 (USD Million)
Table 27 Global Microarray Market Size, By Country/Region, 2013-2020 (USD Million)
Table 28 Global PCR Market Size, By Country/Region, 2013-2020 (USD Million)
Table 29 Global Proteomics Market Size, By Country/Region, 2013-2020 (USD Million)
Table 30 Global Other Omics Technologies Market Size, By Country/Region, 2013-2020 (USD Million)
Table 31 Global Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 32 Global Cytogenetics Market Size, By Country, 2013-2020 (USD Million)
Table 33 Global Ish Market Size, By Country, 2013-2020 (USD Million)
Table 34 Global Other Cytogenetics Market Size, By Country, 2013-2020 (USD Million)
Table 35 Global Imaging Technologies Market Size, By Country, 2013-2020 (USD Million)
Table 36 Global Bioinfromatics Market Size, By Country, 2013-2020, USD Million
Table 37 Global Cancer Biomarkers Market Size, By Application
Table 38 Global Cancer Biomarkers Market for Diagnostics, By Country/Region, 2013-2020 (USD Million)
Table 39 Global Market for Drug Discovery and Development, By Country/Region, 2013-2020 (USD Million)
Table 40 Global Cancer Biomarkers Market for Prognostics, By Country/Region, 2013-2020 (USD Million)
Table 41 Global Cancer Biomarkers Market for Risk Assessment, By Country/Region, 2013-2020 (USD Million)
Table 42 Global Cancer Biomarkers Market for Other Applications, By Country/Region, 2013-2020 (USD Million)
Table 43 Global Cancer Biomarkers Market Size, By Region, 2013-2020 (USD Million)
Table 44 North America :Cancer Biomarkers Market Size, By Country, 2013-2020, (USD Million)
Table 45 North America: Market Size, By Tumor Type, 2013-2020,  (USD Million)
Table 46 North America: Market Size, By Type, 2013-2020, (USD Million)
Table 47 North America: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 48 North America: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 49 North America: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 50 North America: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 51 North America: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 52 North America: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 53 U.S.: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020,  (USD Million)
Table 54 U.S.: Market Size, By Type, 2013-2020, (USD Million)
Table 55 U.S.: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 56 U.S.: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 57 U.S.: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 58 U.S.: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 59 U.S.: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 60 U.S.: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 61 Canada: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020,  (USD Million)
Table 62 Canada: Market Size, By Type, 2013-2020,  (USD Million)
Table 63 Canada: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020,  (USD Million)
Table 64 Canada: Omics Technologies Market Size, By Type, 2013-2020,  (USD Million)
Table 65 Canada: Genomics Technologies Market Size, By Type, 2013-2020,  (USD Million)
Table 66 Canada: Immunoassays Market Size, By Type, 2013-2020,  (USD Million)
Table 67 Canada: Cytogenetics Market Size, By Type, 2013-2020,  (USD Million)
Table 68 Canada: Cancer Biomarkers Market Size, By Application, 2013-2020,  (USD Million)
Table 69 Europe: Market Size, By Country, 2013-2020, (USD Million)
Table 70 Europe: Market Size, By Tumor Type, 2013-2020,   (USD Million)
Table 71 Europe: Cancer Biomarkers Market Size, By Type, 2013-2020,  (USD Million)
Table 72 Europe: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020,  (USD Million)
Table 73 Europe: Omics Technologies Market Size, By Type, 2013-2020,  (USD Million)
Table 74 Europe: Genomics Technologies Market Size, By Type, 2013-2020,  (USD Million)
Table 75 Europe: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 76 North America: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 77 Europe: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 78 Germany: Market Size, By Tumor Type, 2013-2020,  (USD Million)
Table 79 Germany: Market Size, By Type, 2013-2020, (USD Million)
Table 80 Germany: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 81 Germany: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 82 Germany: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 83 Germany: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 84 Germany: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 85 Germany: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 86 U.K.: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 87 U.K.: Market Size, By Type, 2013-2020, (USD Million)
Table 88 U.K.: Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 89 U.K.: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 90 U.K.: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 91 U.K.: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 92 U.K.: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 93 U.K.: Cancer Biomarkers Market Size, By Application , 2013-2020, (USD Million)
Table 94 France: Cancer Biomarkers Market Size, By Tumor Type,2013-2020 (USD Million)
Table 95 France: Cancer Biomarkers Market Size, By Type,2013-2020 (USD Million)
Table 96 France: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 97 France: Omics Technologies Market Size, By Type ,2013-2020 (USD Million)
Table 98 France: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 99 France: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 100 France: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 101 France: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 102 Italy: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 103 Italy: Market Size, By Type,2013-2020 (USD Million)
Table 104 Italy: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 105 Italy: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 106 Italy: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 107 Italy: Immunoassays Market Size, By Type ,2013-2020 (USD Million)
Table 108 Italy: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 109 Italy: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 110 Spain: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 111 Spain: Market Size, By Type,2013-2020 (USD Million)
Table 112 Spain: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 113 Spain: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 114 Spain: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 115 Spain: Immunoassays Market Size, By Type ,2013-2020 (USD Million)
Table 116 Spain: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 117 Spain: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 118 RoE: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 119 RoE: Market Size, By Type,2013-2020 (USD Million)
Table 120 RoE: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 121 RoE: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 122 RoE: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 123 RoE: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 124 RoE: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 125 RoE: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 126 Asia-Pacific: Cancer Biomarkers Market Size, By Country,2013-2020 (USD Million)
Table 127 Asia-Pacific: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 128 Asia-Pacific: Market Size, By Type,2013-2020 (USD Million)
Table 129 Asia-Pacific Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 130 Asia-Pacific Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 131 Asia-Pacific: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 132 Asia-Pacific: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 133 Asia-Pacific: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 134 Asia-Pacific: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 135 Japan: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 136 Japan: Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 137 Japan: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 138 Japan: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 139 Japan: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 140 Japan: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 141 Japan: Cytogenetics Market Size, By Type , 2013-2020 (USD Million)
Table 142 Japan: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 143 China: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 144 China: Market Size, By Type, 2013-2020 (USD Million)
Table 145 China: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 146 China: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 147 China: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 148 China: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 149 China: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 150 China: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 151 India: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 152 India: Market Size, By Type, 2013-2020 (USD Million)
Table 153 India: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 154 India: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 155 India: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 156 India: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 157 India: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 158 India: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 159 RoAPAC: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 160 RoAPAC: Market Size, By Type, 2013-2020 (USD Million)
Table 161 RoAPAC: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 162 RoAPAC: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 163 RoAPAC: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 164 RoAPAC: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 165 RoAPAC: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 166 RoAPAC: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 167 RoW: Market Size, By Country, 2013-2020 (USD Million)
Table 168 RoW: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 169 RoW: Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 170 RoW: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 171 RoW: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 172 RoW: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 173 RoW: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 174 RoW: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 175 RoW: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 176 Latin America: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 177 Latin America: Market Size, By Type, 2013-2020 (USD Million)
Table 178 Latin America: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 179 Latin America: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 180 Latin America: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 181 Latin America: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 182 Latin America: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 183 Latin America: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 184 Middle East and Africa: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 185 Middle East and Africa: Market Size, By Type, 2013-2020 (USD Million)
Table 186 Middle East and Africa: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 187 Middle East and Africa: Omics Technologies Market Size, By Type , 2013-2020 (USD Million)
Table 188 Middle East and Africa: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 189 Middle East and Africa: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 190 Middle East and Africa: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 191 Middle East and Africa: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)

List of Figures (38 Figureas)

Figure 1 Global Cancer Biomarkers Market
Figure 2 Research Methodology
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Cancer Biomarkers Market Size, By Technology, 2014 vs 2019 ($Million)
Figure 8 Global Cancer Biomarkers Market Size, By Accessories, 2014 vs 2019 ($Million)
Figure 9 Global Market Size, By End User, 2014 vs 2019 ($Million)
Figure 10 Market Share, 2013
Figure 11 Cancer Biomarkers Market, By Type
Figure 12 Cancer Biomarkers Market, By Tumor Type
Figure 13 Cancer Biomarkers Market, By Profiling Technologies
Figure 14 Cancer Biomarkers Market, By Application
Figure 15 Market: Drivers, Restraints, Opportunitites, and Challenges
Figure 16 Global Cancer Incidence , 2008–2025
Figure 17 Single- Use Or Disposable Products and One-Stop Shopping are Leading Trends in Market
Figure 18 Porter’s Five Forces Analysis (2014): Increasing Number of Local and Regional Players is Enhancing Competition in the Industry
Figure 19 Strategic Benchmarking: Pall, Sartorius and 3m Adopted Product Launches and Product Enhancement Strategies
Figure 20 Global Cancer Biomarkers Market, By Tumor Type
Figure 21 Cancer Biomarkers Market, By Application: Snapshot (2015-2020):
Figure 22 Geographic Snapshot (2015-2020)
Figure 23 Xx and Xx Hold High Growth Potential for Almost All Market Segments
Figure 24 North America Market Snapshot:
Figure 25 Germany is Major Market for Cancer Biomarkers Market in Europe, 2014
Figure 26 Asia Pacific Cancer Biomarkers Market Shanpshot: China and India are More Lucreative Markets
Figure 27 New Product Launches is the Key Growth Strategy Adopted By Majority of the Leading Players in the Market
Figure 28 Market Share Analysis, By Key Player, 2013
Figure 29 Battle for Market Share: New Product Launches Was the Key Strategy
Figure 30 Geographical Revenue Mix of Key Players in the Market
Figure 31 Abbott Laboratories: Company Snapshot
Figure 32 Affymetrix, Inc.: Company Snapshot
Figure 33 Illumina, Inc.: Company Snapshot
Figure 34 Roche Diagnostics: Company Snapshot
Figure 35 Agilent Technologies, Inc.: Company Snapshot
Figure 36 Merck & Co, Inc.: Company Snapshot
Figure 37 Hologic, Inc.: Company Snapshot
Figure 38 Becton, Dickinson and Company: Company Snapshot

The global cancer biomarkers market is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020. Market growth can be attributed to factors such as rising prevalence of cancer, various technological advancements in omics technologies; increased demand for personalized medicines in cancer therapies; increasing number of clinical trials in developing countries; favorable government research funding for cancer research; and rising R&D expenditures of pharmaceutical companies. However, poorly suited regulatory and reimbursement systems of biomarker tests and high capital investments for biomarker discovery and development are restricting the growth of this market.

In this report, the global cancer biomarkers market is segmented on the basis of type of cancer biomarker, tumor type, profiling technologies, applications, and region. Based on type, the market is segmented into protein biomarkers, genetic biomarkers, and other types of biomarker such as viral, cell, and carbohydrate biomarkers. Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and other type of cancers include such as gastrointestinal stromal tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia. Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics. On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America and Middle East and Africa).

The diagnostics segment accounted for a major share of the cancer biomarkers market, followed by drug discovery and development. This is mainly attributed to rising prevalence of cancer; increasing demand for advanced diagnostics tests; increased awareness and acceptance of diagnostics tests; advancement in technologies; and the need for early-stage cancer diagnosis.

In 2014, North America accounted for the largest share of the global cancer biomarkers market, followed by Europe, Asia-Pacific, and RoW. Growth in the North American market is mainly driven by the increasing government support for discovery and development of biomarkers, rising demand for personalized medicine, early adoption of advanced omics technologies for the biomarker discovery, and increasing use of biomarkers in drug discovery and development by pharmaceutical companies in the region. However, the Asia-Pacific market is expected to witness the highest growth during the forecast period, owing to rising prevalence of cancer, increasing government support, expansions by key market players, and increasing use of biomarker tests for diagnosis in this region.

Prominent players in global cancer biomarkers market are Abbott Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd. (Switzerland), Illumina, Inc. (U.S.), Qiagen NV (Netherlands), Agilent Technologies (U.S.),  Thermo Fisher Scientific Inc. (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.).

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biomarkers Markets on KnowledgeStore
Request Demo